Chantaren et al Table 2 The allele frequency for each single nucleotide polymorphism in this study and other studies in Asians PCV N N 97 713 72 130 511 N Rs1061170 (Y402H) Current study 97 Compiled 1291 studies gotoh et al 19 204 Lee et al20 72 Kondo et al13 130 Hayashi et al9,b 510 nakanishi et al 17 375 Rs800292 (I62V) Current study Compiled studies Lee et al20 Kondo et al13 Hayashi et al9,b Rs10490924 (A69S) Current study 97 Compiled 747 studies Kondo et al18 76 Lee et al20 72 Sakurada et al21 109 gotoh et al 22 55 nakanishi et al 17 375 Fuse et al16 60 Ca 29 (15.0%) 266 (10.3%) 47 (11.5%) 10 (6.9%) 23 (8.8%) 106 (10.4%) 80 (10.7%) Ga 139 (71.7%) 1072 (75.2%) 109 (75.7%) 201 (77.3%) 762 (74.6%) Ta 105 (54.1%) 849 (56.8%) 95 (62.5%) 80 (55.6%) 139 (63.8%) 61 (55.5%) 418 (55.7%) 56 (46.7%) T 165 (85.1%) 2316 (89.7%) 361 (88.5%) 134 (93.1%) 237 (91.2%) 914 (89.6%) 670 (89.3%) A 55 (28.4%) 354 (24.8%) 35 (24.3%) 59 (22.7%) 260 (25.4%) G 89 (45.9%) 645 (43.2%) 57 (37.5%) 64 (44.4%) 79 (36.2%) 49 (44.5%) 332 (44.3%) 64 (53.3%) Controls N 102 2455 n/A 93 173 1342 847 N 102 1604 93 173 1338 N 102 1331 94 93 85 74 847 138 Ca 11 (5.4%) 314 (6.4%) n/A 10 (5.4%) 18 (5.2%) 176 (6.6%) 110 (6.5%) Ga 117 (57.4%) 1871 (58.3%) 113 (60.8%) 197 (56.9%) 1561 (58.3%) Ta 76 (37.3%) 980 (36.8%) 71 (37.8%) 72 (38.7%) 60 (35.3%) 60 (40.5%) 627 (37.0%) 90 (32.6%) T 193 (94.6%) 4596 (93.6%) n/A 176 (94.6%) 328 (94.8%) 2508 (93.4%) 1584 (93.5%) A 87 (42.7%) 1337 (41.7%) 73 (39.2%) 149 (43.1%) 1115 (41.7%) G 128 (62.8%) 1682 (63.2%) 117 (62.2%) 114 (61.3%) 110 (64.7%) 88 (59.5%) 1067 (63.0%) 186 (67.4%) P-value 0.0023 ,0.0001 n/A 0.6438 0.0770 9.73 × 10-5 n/A 0.0034 ,0.0001 0.0045 1.7 × 10-7 n/A 0.0008 ,0.0001 5.7 × 10-6 0.0027 ,0.0001 0.0058 n/A 0.0077 Dovepress Odds ratio (95% CI) 3.081 (1.493–6.360) 2.467 (2.046–2.973) n/A 1.31 (0.47–3.62) 1.77 (0.93–3.35) n/A n/A 1.879 (1.238–2.854) 2.164 (1.883–2.487) 2.01 (1.21–3.36) 2.58 (1.80–3.69) n/A 1.987 (1.331–2.960) 2.259 (1.985–2.571) n/A 1.98 (1.24–3.15) 3.2 (2.1–4.9) 2.0 (1.21–3.29) n/A 1.80 (1.17–2.80) Notes: P-values by Fisher’s exact test; aindicates the risk alleles; bthe allele frequency was calculated from the reported genotype frequency. Abbreviations: PCV, polypoidal choroidal vasculopathy; CI, confidence interval. Asians with PCV (54.1% in the present study and 56.8% in the compiled data) were higher than those in Caucasians with PCV (31.8%).10 In addition, the minor allele frequency (the risk allele frequency in controls) in Asians may also be different from that in Caucasians. The data from this present study and the compiled data indicated that the frequency of the allele C of the Y402H in controls was approximately 6%.9,13,17,20 This is comparable to the frequency of the allele C in controls, 5.1%, from a meta-analysis of association between this SNP and AMD in Asians.23 A meta-analysis of association between this SNP and AMD in Caucasian populations,2 however, indicates a much higher frequency of this allele in controls, 34.9%. For A69S, a meta-analysis of association between this SNP and AMD3 points out that the minor allele frequency is 38.7% in Asians but 21.6% in Caucasians. These data suggest that although the frequency of Y402H or A69S is not uniform in diverse populations, its attributed 468 submit your manuscript | www.dovepress.com Dovepress risk for AMD or PCV exists across them. This supports the notion that the genetic effects of disease-associated variants are usually similar across racial boundaries regard- less of their diverse allelic frequency among different populations.24 Although PCV is different from neovascular AMD in many aspects, such as the affected age group and response to photodynamic therapy, both diseases share some similarities. Both are diseases of abnormal choroidal vessels, and both respond to anti-vascular endothelial growth factor (anti-VEGF) agent by absorption of exudates and extravascular fluid.25,26 This response to anti-VEGF, along with evidence that elevated C-reactive protein (CRP) levels is strongly associated with both PCV and AMD,27 suggests that inflammation plays a role in both diseases. CFH is a critical negative regulator of complement activation and inflammation. The Y402H variant is located within complement control protein 7, one of the complement Clinical Ophthalmology 2012:6